Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer

University of Alabama at Birmingham

Overview

This clinical study will investigate the utility of PET imaging with \[89Zr\]Panitumumab for imaging of EGFR expression in newly diagnosed colon cancer patients to assess lymph node involvement. If promising, this data will be used to design larger trials.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Conditions

Metastatic Colon Cancer

Interventions

[89Zr]Panitumumab PET-MRIDRUG

All patients entered into the study will have \[89Zr\]Panitumumab-PET/MRI imaging.

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Be at least 19 years of age. * Diagnosis of colon cancer * Scheduled to undergo surgical resection Exclusion Criteria: * Inability to provide informed consent * Pregnancy * Inability to lie still for the imaging study * Weight over 350 lbs., due to the scanner bore size * Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos) * Inability to receive Omnipaque (iohexol) iodinated contrast * Inability to receive glucagon * Inability to receive Eovist (gadoxetate disodium) gadolinium based contrast agent * Allergy to contrast imaging agents * Finding or suspicion of distant metastases on CT

Outcomes

Primary Outcomes

Image Quality

Diagnostic image quality of \[89Zr\]Panitumumab PET imaging in patients with newly diagnosed colon cancer with nodal involvement. Standardized Uptake Values (SUVs) will be measured.

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.